Alumis
Precision immunotherapy treatments for immune-mediated diseases
- Sector
- Biotech
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Founded
- 2021
- Latest Form D
- $40M, Jul 2024
- Total capital
- $240M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $240M
- 4 Form D · last Jul 2024
- 27 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 34 pending · first 2021
- Rank in peer group#245 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$40M
- Private capital raisedForm D · SEC · 3rd filing$129M
- Private capital raisedForm D · SEC · 2nd filing$60M
- Private capital raisedForm D · SEC · 1st filing$10.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#245 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan ColowickDirectorNamed in SEC Form D filings
- David M. GoldsteinExecutive OfficerNamed in SEC Form D filings
- Derrick R. RichardsonExecutive OfficerNamed in SEC Form D filings
- James TananbaumDirectorNamed in SEC Form D filings
- John R. SchroerExecutive OfficerNamed in SEC Form D filings
- Jorn DrappaExecutive OfficerNamed in SEC Form D filings
Show all 16 people
- Julian BakerDirectorNamed in SEC Form D filings
- Mark BradleyExecutive OfficerNamed in SEC Form D filings
- Martin BablerExecutive Officer, DirectorNamed in SEC Form D filings
- Patrick B. MachadoDirectorNamed in SEC Form D filings
- Richard GasterDirectorNamed in SEC Form D filings
- Roy C. HardimanExecutive OfficerNamed in SEC Form D filings
- Sapna B. SrivastavaDirectorNamed in SEC Form D filings
- Sara R. KleinExecutive OfficerNamed in SEC Form D filings
- Srinivas R. AkkarajuDirectorNamed in SEC Form D filings
- Zhengbin B. YaoDirectorNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 40- GrantedTYK2 Inhibitors And Uses ThereofUSPTOUS 12,679,850
- PendingCrystalline Forms Of A TYK2 Inhibitor And Uses ThereofUSPTOApplication 19119264
- PendingTYK2 Inhibitors And Uses ThereofUSPTOApplication 19206459
Show all 40 patent records
- TYK2 Inhibitors And Uses ThereofJul 14, 2026 · US 12,679,850Granted
- Crystalline Forms Of A TYK2 Inhibitor And Uses ThereofMay 21, 2026 · Application 19119264Pending
- TYK2 Inhibitors And Uses ThereofMay 7, 2026 · Application 19206459Pending
- Crystalline Forms Of A TYK2 Inhibitor And Uses ThereofDec 11, 2025 · Application 19110181Pending
- TYK2 Inhibitors And Uses ThereofSep 4, 2025 · Application 19213418Pending
- Substituted 1,2,4-TRIAZOLES As TYK2 InhibitorsJul 8, 2025 · US 12,351,572Granted
- TYK2 Inhibitors And Uses ThereofJul 3, 2025 · Application 18847389Pending
- TYK2 Inhibitors And Uses ThereofJun 26, 2025 · Application 18852039Pending
- TYK2 Inhibitors And Uses ThereofJun 12, 2025 · Application 18847381Pending
- Substituted 1,2,4-TRIAZOLES As Intermediates In The Synthesis Of TYK2 InhibitorsAug 13, 2024 · US 12,060,343Granted
- Substituted Pyridazines As TYK2 InhibitorsJun 11, 2024 · US 12,006,306Granted
- Substituted 1,2,4-TRIAZOLES As Intermediates In The Syntheisis Of TYK2 InhibitorsAug 22, 2023 · US 11,731,956Granted
- TYK2 Inhibitors And Uses ThereofJun 9, 2022 · Application 17438329Pending
- Substituted Pyridines As TYK2 InhibitorsJul 6, 2021 · US 11,053,219Granted
- Crystalline Forms Of A TYK2 Inhibitor And Uses ThereofApplication 63671870Pending
- Methods Of Treating Hidradenitis SuppurativaApplication PCTUS2024016104Pending
- Methods Of Treating Dermatological DisordersApplication PCTUS2024016103Pending
- Crystalline Forms Of A TYK2 Inhibitor And Uses ThereofApplication PCTUS2023076405Pending
- Methods Of Treating Dermatological DisordersApplication 19157136Pending
- Immediate-release Formulations Of A TYK2 InhibitorApplication 63583934Pending
- Crystalline Forms Of A TYK2 Inhibitor And Uses ThereofApplication PCTUS2023073918Pending
- Crystalline Forms Of A TYK2 Inhibitor And Uses ThereofApplication PCTUS2023021986Pending
- TYK2 Inhibitors And Uses ThereofApplication PCTUS2023016677Pending
- TYK2 Inhibitors And Uses ThereofApplication PCTUS2023064517Pending
- TYK2 Inhibitors And Uses ThereofApplication PCTUS2023064520Pending
- Methods Of Treating Hidradenitis SuppurativaApplication 63485397Pending
- Methods Of Treating Dermatological DisordersApplication 63485409Pending
- TYK2 Inhibitors And Uses ThereofApplication 63429720Pending
- Crystalline Forms Of A TYK2 Inhibitor And Uses ThereofApplication 63417092Pending
- Crystalline Forms Of A TYK2 Inhibitor And Uses ThereofApplication 63414665Pending
- TYK2 Inhibitors And Uses ThereofApplication 63408572Pending
- Crystalline Forms Of A TYK2 Inhibitor And Uses ThereofApplication 63405582Pending
- Crystalline Forms Of A TYK2 Inhibitor And Uses ThereofApplication 63405577Pending
- TYK2 Inhibitors And Uses ThereofApplication 63344126Pending
- Crystalline Forms Of A TYK2 Inhibitor And Uses ThereofApplication 63341528Pending
- TYK2 Inhibitors And Uses ThereofApplication 63324754Pending
- TYK2 Inhibitors And Uses ThereofApplication 63320318Pending
- TYK2 Inhibitors And Uses ThereofApplication 63320320Pending
- TYK2 Inhibitors And Uses ThereofApplication PCTUS2025059671Pending
- Immediate-release Formulations Of A TYK2 InhibitorApplication 19521091Pending
Related companies, and why
- EtiomeSimilar federal contract value in Biotech · null in contracts
- TEMPRIAN ONCOLOGY, INC.Similar federal contract value in Biotech · null in contracts
- Vividion TherapeuticsSimilar federal contract value in Biotech · null in contracts
- AUCTUS BIOLOGICS, INC.Similar federal contract value in Biotech · null in contracts
- VIOME LIFE SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- IMMUDX, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .